JAMA Intern Med: Kramycin increases bleeding risk in senior DOAC populations

Kramycin is a commonantibioticthat increases the concentration of blood medicine simply oral anticoagulants (DOACs) and increases the risk of bleedingRecently, researchers compared the effects of azithromycin and clamycin treatment on the risk of bleeding in elderly PATIENTs with DOAC within 30 dayspatients treated with DOAC (Dabiga,Apixabanor Deva Saban) in Ontario, Canada, from 23 June 2009 to 31 December 2016, were treated with kramycin (n?6592) or azithromycin (n?18351), with an average age of 77.6 years, with the main endpoint beingthe digestive tract(, the24,943 patients, 12,493 women, of which Leva chaban was the most commonly used DOAC (9972 patients (40.0%), followed by Apixaban (7953 (31.9%)) and Dabbiga Group (7018 (28.1%)The study found that the combination of clathromycin and DOAC led to an increased risk of hospitalization for haemorrhage (51 out of 6592 patients , 0.77% , vs, 79 cases in 18351 patients , and an adjusted risk ratio of 1.71 and an absolute risk difference of 0.34%)study found that for older patients who were taking direct oral anticoagulants, combined with cyclomycin increased the risk of hospitalization for haemorrhage for 30 days compared to azithromycin